Drug Profile
Research programme: eye disorder therapies - Kiora Pharmaceuticals/GlaxoSmithKline
Latest Information Update: 15 Nov 2021
Price :
$50
*
At a glance
- Originator EyeGate Pharma; GlaxoSmithKline
- Developer GSK; Kiora Pharmaceuticals
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 08 Nov 2021 EyeGate Pharma is now called Kiora Pharmaceuticals
- 11 Apr 2018 The USPTO issues a patent (no.9 937 074) to EyeGate Pharmaceuticals covering the utility of iontophoretic contact lens technology
- 16 Jul 2016 No recent reports of development identified for preclinical development in Eye-disorders in USA (Ophthalmic)